about
Pathophysiological considerations of seizures, epilepsy, and status epilepticus in the elderlyCognitive decline in severe intractable epilepsy.Role of valproate across the ages. Treatment of epilepsy in the elderly.Knowledge about and Attitude towards Epilepsy among Menit Community, Southwest Ethiopia.Cognitive Effects of Low-dose Topiramate Compared with Oxcarbazepine in Epilepsy PatientsFamilial vulnerability to an unusual cognitive adverse effect of topiramate: Discussion of mechanisms.Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.Subjective memory evaluation before and after temporal lobe epilepsy surgery.New drugs for the treatment of epilepsy: a practical approachExecutive functions in chronic mesial temporal lobe epilepsySafety and tolerability of emerging pharmacological treatments for bipolar disorder.Idiopathic generalised epilepsy: a pilot study of memory and neuronal dysfunction in the temporal lobes, assessed by magnetic resonance spectroscopyDevelopment and validation of the Pediatric Epilepsy Side Effects Questionnaire.Optimizing antiepileptic drug therapy in the elderly.Levetiracetam improves verbal memory in high-grade glioma patients.Optimizing epilepsy management in teenagers.Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin.Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.Treatment and management of epilepsy in the elderly demented patient.Cognitive effects of antiepileptic drugs.Comparison of cognitive effects of lamotrigine and oxcarbazepine in epilepsy patients.Seizures in the elderly: impact on mental status, mood, and sleep.The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memoryPharmacokinetic and pharmacodynamic properties of the new AEDs: A review articleGABAergic drugs in the treatment of epilepsy: modern or outmoded?The efficacy and safety of newer anticonvulsants in patients with dementia.Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview.Topiramate and cognitive impairment: evidence and clinical implications.Zebrafish as a Model for Epilepsy-Induced Cognitive Dysfunction: A Pharmacological, Biochemical and Behavioral Approach.Turning down the volume: Astrocyte volume change in the generation and termination of epileptic seizures.Anticonvulsive and neuroprotective effects of synergetic combination of phenytoin and gastrodin on the convulsion induced by penicillin in mice.Evaluation of the role of chronic daily melatonin administration and pinealectomy on penicillin-induced focal epileptiform activity and spectral analysis of ECoG in rats: an in vivo electrophysiological study.Lamotrigine-induced rash--worth a rechallenge.Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers.Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.Effect of gabapentin on cognitive processes in rats not exposed and exposed to tobacco smoke during fetal life.Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy.Impaired motor control in patients with benign focal epilepsy of childhood.Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate.Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy.
P2860
Q28397308-D83FA281-7749-470C-814C-B3DDFC0BDC93Q33153320-BB496E03-707A-446A-B25A-085FA961D57BQ33153941-B5675CD8-E9C8-46E5-AEEE-8A83CC89946BQ33559803-2EDB03F5-8A90-4DF3-BE98-09BC068197CFQ33790784-E2B0F7E0-A642-4910-A6BE-CF22F0421DD0Q34345252-D00A6150-8B59-4C24-BB82-6D4BAF138302Q35086171-E6ECCD33-452E-4AFE-878E-DAEA14E735C3Q35137280-F913BBCE-04B9-4D09-A5AF-81DFC267BFA3Q35520425-893E1DF3-2E81-4003-AD64-3D66C02013A0Q36192402-C97DCD21-CD25-4ED3-B769-397935C8F703Q36199036-42CFC0A6-503C-4F80-844A-0728BD051662Q36226575-F6AF0C07-F328-4F7D-98D3-A5EA684275AAQ36229828-C9F11F85-DE0C-49DC-809D-31BA63EC1BF9Q36270316-9B38E9BB-737A-4740-BBA2-2CE055793D2BQ36544087-BF4E59A6-5295-46FC-80CD-B70F5761CFB6Q36561919-D31CE50B-9EEB-4E48-BEBC-652150834DADQ36762432-1B4F2C09-C0B6-4AEE-873F-886BB955BA01Q37164665-BCC53915-674D-45E1-BFF5-8D21A5ECAD90Q37178698-457DD073-79D2-4F90-954E-7EDCF6A4F410Q37203325-0F840E99-F7A3-4013-9C4E-2A7DEF245ECCQ37203504-34E85EDC-FBB3-48B9-8494-2C4B42F1E2ABQ37226443-E90A2230-7FD5-4255-9329-98779D0C5C80Q37244159-307465A6-F21A-4F2C-9590-3047ABE907CBQ37311819-0765CE48-E08A-462C-8C75-8AA34FAFF1F5Q37856281-0174AE20-D2B6-4826-92B6-E0F71389CB68Q38021819-FDEEC61E-58B4-4CFC-A48B-49575E0C147AQ38033603-29EE4E43-C6CD-4DEC-A11C-59E22C47291AQ38235953-A6DFC734-6361-436D-96A6-E4F2B5D146D8Q38639861-B489619F-DEE1-452A-B816-FD5BDB8B5F91Q39259432-324CC40D-AAA7-4ED5-A831-FD35A0C6157FQ41712566-7AA38CA7-7192-4D45-B901-192ACCBD547FQ43974978-617142C6-93EF-48AB-A1B8-5B0D7EC12F4BQ44763147-7CDC1303-1F61-469C-9855-6BD4274F218AQ45059187-6495AB16-79D4-4EC6-8DBF-9F7153038093Q46061246-B244AE07-543D-41AD-AE85-22C54322BF53Q46094285-91A3FB15-A031-477B-86CE-80C65A23396EQ46298140-7DFB2CD5-5BD3-4EE4-B61F-D50F68B90824Q46352432-F7F84060-5104-4B1E-8DDD-8C5DD1FA1C10Q46505592-EA5E71F3-3760-484B-95B1-37D9B925E8C2Q46648136-6F9F8860-203C-408C-A747-152C42C9A15F
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Newer antiepileptic drugs and cognitive issues.
@ast
Newer antiepileptic drugs and cognitive issues.
@en
type
label
Newer antiepileptic drugs and cognitive issues.
@ast
Newer antiepileptic drugs and cognitive issues.
@en
prefLabel
Newer antiepileptic drugs and cognitive issues.
@ast
Newer antiepileptic drugs and cognitive issues.
@en
P2093
P2860
P1433
P1476
Newer antiepileptic drugs and cognitive issues.
@en
P2093
Albert P Aldenkamp
Marc De Krom
Rianne Reijs
P2860
P356
10.1046/J.1528-1157.44.S4.3.X
P478
44 Suppl 4
P577
2003-01-01T00:00:00Z